PHSC (PHSC)

Sector:

Support

Index:

FTSE AIM All-Share

 8.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 15.00p
  • 52 Week Low: 8.00p
  • Currency: UK Pounds
  • Shares Issued: 14.68m
  • Volume: 0
  • Market Cap: £1.17m
  • RiskGrade: 311

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Date: Friday 26 Nov 2010

LONDON (ShareCast) - Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities.

The company also announced that it has completed proof of concept trials on delivering RPL554 via each of the main types of devices commonly available for inhalation therapy.

“These studies broaden the inhalational delivery devices available to potential licensees of RPL554 and will enable licensees to test and administer the drug in the principal devices used for existing respiratory drug treatments,” said Professor Michael Walker, chief executive of Verona. “Furthermore, with many inhaler devices having strong utility patents, it allows the possibility to further strengthen the patent protection for RPL554," Professor Walker added.

Health and safety consultancy PHSC saw its shares take a tumble after interim earnings virtually halved and the company warned of the negative effects of the recent comprehensive spending review by the government. Earnings before interest, tax, depreciation and amortisation in the six months to 30 September fell to £0.11m from £0.21m the year before on turnover that rose 8% to £2.39 from £2.21m.

“There will be reductions in work that we do directly for public sector organisations, but less easy to evaluate is how our private sector clients who themselves rely upon public funding may be impacted,” the company’s chief executive Stephen King warned.

Debt management firm Sterling Green moved into the black at the interim stage and remains hopeful of delivering a modest full year maiden profit.

Total revenue rose to £1.32m in the six months to 30 September from £1.14m the year before as the number of debt management clients rose to 4,216 from 3,120. Pre-tax profit was £38,000, compared to a loss of £41,000 the year before.




Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

PHSC Market Data

Currency UK Pounds
Share Price 8.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 15.00p
52 Week Low 8.00p
Volume 0
Shares Issued 14.68m
Market Cap £1.17m
RiskGrade 311

PHSC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
5.88% below the market average5.88% below the market average5.88% below the market average5.88% below the market average5.88% below the market average
8.41% below the sector average8.41% below the sector average8.41% below the sector average8.41% below the sector average8.41% below the sector average
Price Trend
41.04% below the market average41.04% below the market average41.04% below the market average41.04% below the market average41.04% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Income
7.19% above the market average7.19% above the market average7.19% above the market average7.19% above the market average7.19% above the market average
1.37% above the sector average1.37% above the sector average1.37% above the sector average1.37% above the sector average1.37% above the sector average
Growth
55.8% below the market average55.8% below the market average55.8% below the market average55.8% below the market average55.8% below the market average
59.62% below the sector average59.62% below the sector average59.62% below the sector average59.62% below the sector average59.62% below the sector average

PHSC Dividends

  Latest Previous
  Interim Final
Ex-Div 02-Jan-20 26-Sep-19
Paid 28-Feb-20 11-Oct-19
Amount 0.50p 0.50p

Trades for --2020

Time Volume / Share Price
0 @ 0.000p

PHSC Key Personnel

CEO Stephen A King

Top of Page